Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Hope Rugo

Hope Rugo

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
What to look forward to in breast cancer at ASCO 2023 3:24
What to look forward to in breast cancer at ASCO 2023
Hope Rugo • 12 May 2023
KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs 4:01
KEYNOTE-355: outcomes in pts discontinuing chemo before pembro and in pts with immune-mediated AEs
Hope Rugo • 12 May 2023
Detailed safety analysis from the DESTINY-Breast04 trial 6:33
Detailed safety analysis from the DESTINY-Breast04 trial
Hope Rugo • 12 May 2023
Hot topics in breast cancer in 2023 – what is coming next? 4:04
Hot topics in breast cancer in 2023 – what is coming next?
Hope Rugo • 6 Dec 2022
MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC 4:03
MonarchE 4-year: abemaciclib + endocrine therapy for HR+, HER2-, node-positive, high-risk early BC
Hope Rugo • 7 Dec 2022
BYLieve Study Cohort A: alpelisib + ET in PIK3CA-mutant, HR+, HER2-, advanced breast cancer 3:07
BYLieve Study Cohort A: alpelisib + ET in PIK3CA-mutant, HR+, HER2-, advanced breast cancer
Hope Rugo • 7 Dec 2022
CAPItello-291: capivasertib +fulvestrant for AI-resistant HR+/HER2- advanced breast cancer 5:28
CAPItello-291: capivasertib +fulvestrant for AI-resistant HR+/HER2- advanced breast cancer
Hope Rugo • 7 Dec 2022
2nd interim analysis of OS from TROPiCS-02: SG in HR+/HER2- breast cancer 4:38
2nd interim analysis of OS from TROPiCS-02: SG in HR+/HER2- breast cancer
Hope Rugo • 7 Dec 2022
Striving for equitable healthcare 2:25
Striving for equitable healthcare
Hope Rugo • 5 Jun 2022
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC 5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
Hope Rugo • 5 Jun 2022
TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBC 5:07
TROPiCS-02: sacituzumab govetican improves PFS versus physicians choice for HR+/HER2- mBC
Hope Rugo • 5 Jun 2022
Sequencing novel HER2-targeted therapies in metastatic breast cancer 3:32
Sequencing novel HER2-targeted therapies in metastatic breast cancer
Hope Rugo • 26 Mar 2021
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer 5:06
Safety outcomes in the Phase III monarchE trial of abemaciclib + ET in HR+, HER2- breast cancer
Hope Rugo • 26 Mar 2021
Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer? 3:23
Should chemotherapy be used in post-menopausal patients with low genomic risk HR+ breast cancer?
Hope Rugo • 26 Mar 2021
Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts 5:14
Adding alpelisib for HR+/HER2- advanced breast cancer in SOLAR-1: adverse event impacts
Hope Rugo • 29 Sep 2019
BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO 3:01
BYLieve additional cohort: update on the trial of alpelisib in advanced breast cancer from ESMO
Hope Rugo • 29 Sep 2019
The content of VJOncology is intended for healthcare professionals